XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Testing revenue $ 211.5 $ 183.5 $ 413.7 $ 364.7
Costs and expenses:        
Cost of testing revenue 64.4 57.8 128.9 117.0
Research and development expense 27.1 21.2 52.7 43.7
Selling, general, and administrative expense 144.9 140.7 284.9 292.4
Legal settlements 0.0 77.5 0.0 77.5
Goodwill and long-lived asset impairment charges 11.6 0.0 11.6 0.0
Total costs and expenses 248.0 297.2 478.1 530.6
Operating loss (36.5) (113.7) (64.4) (165.9)
Other income (expense):        
Interest income 0.4 0.5 1.0 1.2
Interest expense (0.8) (0.5) (1.3) (1.0)
Other (0.3) (2.4) 1.6 (3.0)
Total other income (expense), net (0.7) (2.4) 1.3 (2.8)
Loss before income tax (37.2) (116.1) (63.1) (168.7)
Income tax (benefit) expense (0.5) 0.0 (0.4) 2.1
Net loss $ (36.7) $ (116.1) $ (62.7) $ (170.8)
Net loss per share:        
Basic (dollars per share) $ (0.41) $ (1.42) $ (0.69) $ (2.10)
Diluted (dollars per share) $ (0.41) $ (1.42) $ (0.69) $ (2.10)
Weighted average shares outstanding:        
Basic (shares) 90.6 81.7 90.3 81.5
Diluted (shares) 90.6 81.7 90.3 81.5
Revenue from contract with customer, product and service, extensible enumeration Testing [Member] Testing [Member] Testing [Member] Testing [Member]
Cost, product and service, extensible enumeration Testing [Member] Testing [Member] Testing [Member] Testing [Member]